175 related articles for article (PubMed ID: 10999723)
1. Clinical relevance of the lung resistance protein in diffuse large B-cell lymphomas.
Filipits M; Jaeger U; Simonitsch I; Chizzali-Bonfadin C; Heinzl H; Pirker R
Clin Cancer Res; 2000 Sep; 6(9):3417-23. PubMed ID: 10999723
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical expression of multidrug resistance proteins as a predictor of poor response to chemotherapy and prognosis in patients with nodal diffuse large B-cell lymphoma.
Ohsawa M; Ikura Y; Fukushima H; Shirai N; Sugama Y; Suekane T; Hirayama M; Hino M; Ueda M
Oncology; 2005; 68(4-6):422-31. PubMed ID: 16020972
[TBL] [Abstract][Full Text] [Related]
3. [Expression and prognostic value of the drug resistance markers P-gp, Mrp1, Mrp2, and Lrp in ovarian carcinoma].
Katsaros D; Fracchioli S; Arts HJ; de Vries EG; Danese S; Richiardi G; Arisio R; Gordini G; Van der Zee AG; Suurmeijer AJ; Massobrio M
Minerva Ginecol; 1999 Dec; 51(12):463-70. PubMed ID: 10767994
[TBL] [Abstract][Full Text] [Related]
4. [Treatment of primary mediastinal large B-cell lymphomas].
Schneider T; Tóth E; Molnár Z; Várady E; Deák B; Horváth A; Horváth GI; Eid H; Schneider K; Lovey J; Keresztes S; Esik O; Lengyel Z; Rosta A
Orv Hetil; 2004 Dec; 145(50):2531-7. PubMed ID: 15662753
[TBL] [Abstract][Full Text] [Related]
5. Effect of combination chemotherapy with cefoperazone on non-Hodgkin's lymphoma.
Natazuka T; Matsui T; Ito M; Sugimoto T; Nakao Y; Fujita T
Leuk Res; 1992; 16(4):417-8. PubMed ID: 1373460
[No Abstract] [Full Text] [Related]
6. Expression of multidrug resistance proteins P-glycoprotein, multidrug resistance protein 1, breast cancer resistance protein and lung resistance related protein in locally advanced bladder cancer treated with neoadjuvant chemotherapy: biological and clinical implications.
Diestra JE; Condom E; Del Muro XG; Scheffer GL; Pérez J; Zurita AJ; Muñoz-Seguí J; Vigués F; Scheper RJ; Capellá G; Germà-Lluch JR; Izquierdo MA
J Urol; 2003 Oct; 170(4 Pt 1):1383-7. PubMed ID: 14501774
[TBL] [Abstract][Full Text] [Related]
7. Expression of multidrug resistance 1 (MDR1), multidrug resistance-related protein 1 (MRP1), lung resistance protein (LRP), and breast cancer resistance protein (BCRP) genes and clinical outcome in childhood acute lymphoblastic leukemia.
Kourti M; Vavatsi N; Gombakis N; Sidi V; Tzimagiorgis G; Papageorgiou T; Koliouskas D; Athanassiadou F
Int J Hematol; 2007 Aug; 86(2):166-73. PubMed ID: 17875533
[TBL] [Abstract][Full Text] [Related]
8. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group Study.
Leith CP; Kopecky KJ; Chen IM; Eijdems L; Slovak ML; McConnell TS; Head DR; Weick J; Grever MR; Appelbaum FR; Willman CL
Blood; 1999 Aug; 94(3):1086-99. PubMed ID: 10419902
[TBL] [Abstract][Full Text] [Related]
9. Expression of MRP1, BCRP, LRP, and ERCC1 in advanced non-small-cell lung cancer: correlation with response to chemotherapy and survival.
Li J; Li ZN; Du YJ; Li XQ; Bao QL; Chen P
Clin Lung Cancer; 2009 Nov; 10(6):414-21. PubMed ID: 19900859
[TBL] [Abstract][Full Text] [Related]
10. Multidrug resistance (MDR-1) expression in AIDS-related lymphomas.
Tulpule A; Sherrod A; Dharmapala D; Young LL; Espina BM; Sanchez MN; Gill PS; Levine AM
Leuk Res; 2002 Feb; 26(2):121-7. PubMed ID: 11755462
[TBL] [Abstract][Full Text] [Related]
11. RNA expression of breast cancer resistance protein, lung resistance-related protein, multidrug resistance-associated proteins 1 and 2, and multidrug resistance gene 1 in breast cancer: correlation with chemotherapeutic response.
Burger H; Foekens JA; Look MP; Meijer-van Gelder ME; Klijn JG; Wiemer EA; Stoter G; Nooter K
Clin Cancer Res; 2003 Feb; 9(2):827-36. PubMed ID: 12576456
[TBL] [Abstract][Full Text] [Related]
12. Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian carcinoma.
Arts HJ; Katsaros D; de Vries EG; Massobrio M; Genta F; Danese S; Arisio R; Scheper RJ; Kool M; Scheffer GL; Willemse PH; van der Zee AG; Suurmeijer AJ
Clin Cancer Res; 1999 Oct; 5(10):2798-805. PubMed ID: 10537344
[TBL] [Abstract][Full Text] [Related]
13. Role of chemotherapy resistance genes in outcome of neuroblastoma.
de Cremoux P; Jourdan-Da-Silva N; Couturier J; Tran-Perennou C; Schleiermacher G; Fehlbaum P; Doz F; Mosseri V; Delattre O; Klijanienko J; Vielh P; Michon J
Pediatr Blood Cancer; 2007 Mar; 48(3):311-7. PubMed ID: 16609945
[TBL] [Abstract][Full Text] [Related]
14. Expression of MRP1, LRP and Pgp in breast carcinoma patients treated with preoperative chemotherapy.
Rudas M; Filipits M; Taucher S; Stranzl T; Steger GG; Jakesz R; Pirker R; Pohl G
Breast Cancer Res Treat; 2003 Sep; 81(2):149-57. PubMed ID: 14572157
[TBL] [Abstract][Full Text] [Related]
15. Prognostic implications of ploidy and proliferative activity in the diffuse, aggressive non-Hodgkin's lymphomas.
Winter JN; Andersen J; Variakojis D; Gordon LI; Fisher RI; Oken MM; Neiman RS; Jiang S; Bauer KD
Blood; 1996 Nov; 88(10):3919-25. PubMed ID: 8916958
[TBL] [Abstract][Full Text] [Related]
16. [Expression of proteins associated with multidrug resistance and resistance to chemotherapy in lung cancer].
Paredes Lario A; Blanco García C; Echenique Elizondo M; Lobo C
Arch Bronconeumol; 2007 Sep; 43(9):479-84. PubMed ID: 17919413
[TBL] [Abstract][Full Text] [Related]
17. Results of CHOP chemotherapy for diffuse large B-cell lymphoma.
Hallack Neto AE; Pereira J; Beitler B; Chamone DA; Llacer PD; Dulley FL; Macedo MC; Chaoubah A
Braz J Med Biol Res; 2006 Oct; 39(10):1315-22. PubMed ID: 16906323
[TBL] [Abstract][Full Text] [Related]
18. Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma.
Filipits M; Drach J; Pohl G; Schuster J; Stranzl T; Ackermann J; Königsberg R; Kaufmann H; Gisslinger H; Huber H; Ludwig H; Pirker R
Clin Cancer Res; 1999 Sep; 5(9):2426-30. PubMed ID: 10499614
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of carboplatin with an MEP (mitoxantrone, etoposide and prednisone) regimen for relapsed and CHOP-resistant diffuse large B-cell lymphomas.
Murohashi I; Kashimura T; Tominaga K; Wakao D; Takahashi T; Akiba M; Kishimoto K; Yoshida K; Yagasaki F; Itoh Y; Sakata T; Kawai N; Itoh K; Suzuki T; Matsuda A; Hirashima K; Bessho M
Leuk Res; 2002 Mar; 26(3):229-34. PubMed ID: 11792410
[TBL] [Abstract][Full Text] [Related]
20. Chemo- and radiation sensitivity of xenografted acute lymphoblastic leukemias--correlation to the expression of multidrug resistance proteins.
Fichtner I; Paal K; Borgmann A; Badiali L; Wurm R; Henze G
Anticancer Res; 2003; 23(3B):2657-64. PubMed ID: 12894554
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
